Advances in research on anti-tumor drug-related renal injury
10.16571/j.cnki.1008-8199.2019.06.019
- VernacularTitle: 抗肿瘤药物相关肾损伤的研究进展
- Author:
Peng-xian SHI
1
;
Gui-sheng REN
1
;
Wei-xin HU
1
Author Information
1. National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing Medical University, General Hospital of Eastern Theater Command, PLA, Nanjing 210002, Jiangsu,China
- Publication Type:Journal Article
- Keywords:
antineoplastic drug;
drug nephrotoxicity;
acute kidney injury
- From:
Journal of Medical Postgraduates
2019;32(6):652-656
- CountryChina
- Language:Chinese
-
Abstract:
Novel antineoplastic drugs have significantly prolonged the survival time of cancer patients. Meanwhile, nephrotoxicity of antineoplastic drugs and its adverse effects on the prognosis of cancer patients have received increasing attention. Conventional chemotherapy causes kidney injury mainly through direct renal toxicity, while new anti-tumor drugs can induce a number of kidney damage, including acute renal tubular injury, thrombotic microangiopathy, interstitial nephritis, and glomerular diseases through multiple mechanisms. Clinicians must be knowledgeable in the renal toxicity of antineoplastic drugs to minimize the nephrotoxicity of the drugs and diagnose early, especially in patients with underlying kidney disease. This article focuses on the risk factors, clinical and histological patterns, pathogenesis, prevention and treatment of renal injury associated with the antineoplastic drugs, especially novel targeted antineoplastic drugs.
